Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
BMY Analyst Ratings
Hold
4 Buy
12 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BMY Stock 12 Month Forecast
Average Price Target
$58.86
▲(16.07% Upside)
| Highest Price Target$70.00 | Average Price Target$58.86 | Lowest Price Target$36.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citi
Reiterated
04/11/25
Raymond James
Reiterated
04/10/25
Morgan Stanley
Reiterated
04/09/25
Goldman Sachs
Initiated
04/08/25
BMO Capital
Reiterated
04/04/25
Bernstein
Reiterated
04/02/25
J.P. Morgan
Reiterated
03/20/25
William Blair
Reiterated
03/11/25
Leerink Partners
Reiterated
03/10/25
Unknown Analyst
Not Ranked
Berenberg Bank
$60
Hold
18.32%
Upside
Reiterated
03/07/25
Wells Fargo
$60→$62
Hold
22.26%
Upside
Reiterated
02/20/25
Bristol-Myers Squibb: Balancing Growth and Challenges Amidst Market Dynamics - A Hold RecommendationWe see cost cuts as good move to right size the co. and understand factors driving '25 guide. Good color on Cobenfy access and tolerability - BMY has achieved >90% access in and is making good progress in commercial, enabling them to track ahead of their goal in driving breadth of usage. In real world, they're seeing patients stay on 50mg (starting dose) for at least 2 weeks (vs. 2 days in trials), with this slower titration leading to lower nausea/vomiting than in trials. They hear of efficacy as early as Wk 1 and improvement in cognition & negative symptoms. Thoughts into Cobenfy ADEPT trials - Despite evidence of xanomeline efficacy in reducing behavioral symptoms such as hallucinations & delusions in Alzheimer's (AD) pts, mgmt noted the importance of managing PBO response in the AD psychosis trials.
Truist Financial
―
Buy
―
Reiterated
02/20/25
Bristol-Myers Squibb (BMY) Receives a Buy from Truist Financial
Deutsche Bank
$55→$53
Hold
4.52%
Upside
Reiterated
02/10/25
Bristol-Myers Squibb Co. (BMY) PT Lowered to $53 at Deutsche BankDeutsche Bank analyst James Shin lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $55.00) while maintaining a Hold rating.
Bank of America Securities
$63
Hold
24.24%
Upside
Reiterated
02/07/25
Tim Anderson's Hold Rating on Bristol-Myers Squibb Due to Limited Upside and Valuation Concerns
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citi
Reiterated
04/11/25
Raymond James
Reiterated
04/10/25
Morgan Stanley
Reiterated
04/09/25
Goldman Sachs
Initiated
04/08/25
BMO Capital
Reiterated
04/04/25
Bernstein
Reiterated
04/02/25
J.P. Morgan
Reiterated
03/20/25
William Blair
Reiterated
03/11/25
Leerink Partners
Reiterated
03/10/25
Unknown Analyst
Not Ranked
Berenberg Bank
$60
Hold
18.32%
Upside
Reiterated
03/07/25
Wells Fargo
$60→$62
Hold
22.26%
Upside
Reiterated
02/20/25
Bristol-Myers Squibb: Balancing Growth and Challenges Amidst Market Dynamics - A Hold RecommendationWe see cost cuts as good move to right size the co. and understand factors driving '25 guide. Good color on Cobenfy access and tolerability - BMY has achieved >90% access in and is making good progress in commercial, enabling them to track ahead of their goal in driving breadth of usage. In real world, they're seeing patients stay on 50mg (starting dose) for at least 2 weeks (vs. 2 days in trials), with this slower titration leading to lower nausea/vomiting than in trials. They hear of efficacy as early as Wk 1 and improvement in cognition & negative symptoms. Thoughts into Cobenfy ADEPT trials - Despite evidence of xanomeline efficacy in reducing behavioral symptoms such as hallucinations & delusions in Alzheimer's (AD) pts, mgmt noted the importance of managing PBO response in the AD psychosis trials.
Truist Financial
―
Buy
―
Reiterated
02/20/25
Bristol-Myers Squibb (BMY) Receives a Buy from Truist Financial
Deutsche Bank
$55→$53
Hold
4.52%
Upside
Reiterated
02/10/25
Bristol-Myers Squibb Co. (BMY) PT Lowered to $53 at Deutsche BankDeutsche Bank analyst James Shin lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $55.00) while maintaining a Hold rating.
Bank of America Securities
$63
Hold
24.24%
Upside
Reiterated
02/07/25
Tim Anderson's Hold Rating on Bristol-Myers Squibb Due to Limited Upside and Valuation Concerns
Best Analysts Covering Bristol Myers
Which Analyst Should I Follow If I Want to Buy BMY and Sell After:
1 Month
xxx
Success Rate
11/20 ratings generated profit
Average Return
+0.14%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.00% of your transactions generating a profit, with an average return of +0.14% per trade.
3 Months
xxx
Success Rate
14/23 ratings generated profit
Average Return
+1.93%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +1.93% per trade.
1 Year
Success Rate
18/23 ratings generated profit
Average Return
+7.16%
reiterated a sell rating 4 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 78.26% of your transactions generating a profit, with an average return of +7.16% per trade.
2 Years
xxx
Success Rate
17/23 ratings generated profit
Average Return
+9.46%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 73.91% of your transactions generating a profit, with an average return of +9.46% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BMY Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
0
0
0
0
0
Buy
10
12
12
11
8
Hold
22
14
15
15
19
Sell
5
4
1
2
2
Strong Sell
0
0
0
0
0
total
37
30
28
28
29
Each month's total comprises the sum of three months' worth of ratings.
BMY Financial Forecast
BMY Stock Forecast FAQ
What is BMY’s average 12-month price target, according to analysts?
Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is $58.86.
What is BMY’s upside potential, based on the analysts’ average price target?
Bristol-Myers Squibb has 16.07% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BMY a Buy, Sell or Hold?
Bristol-Myers Squibb has a consensus rating of Hold which is based on 4 buy ratings, 12 hold ratings and 1 sell ratings.
What is Bristol-Myers Squibb’s price target?
The average price target for Bristol-Myers Squibb is $58.86. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $70.00 ,the lowest forecast is $36.00. The average price target represents 16.07% Increase from the current price of $50.71.
The highest analyst price target is $70.00 ,the lowest forecast is $36.00. The average price target represents 16.07% Increase from the current price of $50.71.
What do analysts say about Bristol-Myers Squibb?
Bristol-Myers Squibb’s analyst rating consensus is a Hold. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of BMY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.